Idexx Laboratories, Inc.
IDEXX Laboratories Announces First Quarter 2026 Financial Results and Updated Guidance
Summary
IDEXX Laboratories, Inc. reported first quarter 2026 financial results with revenue of $1,141 million, a 14% increase as reported and 11% organic. The company achieved EPS of $3.47, an increase of 17% as reported and 15% on a comparable basis. IDEXX raised its 2026 revenue guidance to $4,675 million - $4,760 million, reflecting stronger CAG Diagnostics recurring revenue performance. The company also updated its 2026 EPS outlook to $14.45 - $14.90, supported by increased revenue and operating margin expansion.
Profitelligence Alerts
Get alerts for IDXX
Be first to know when Idexx Laboratories, Inc. files with the SEC.
Filing Categories
Advertisement
About Idexx Laboratories, Inc.
Idexx Laboratories, Inc. is a prominent player in the health technology industry, specializing in veterinary diagnostics, software, and water microbiology testing. The company develops and markets products and services that enhance animal health and well-being, offering a wide range of diagnostic tests for companion animals, livestock, and poultry. It is notably recognized for providing innovative diagnostic services including in-house analyzers and rapid assays, which facilitate quick and accurate diagnostic results for veterinarians. Besides its veterinary focus, Idexx Laboratories also provides water testing solutions aimed at ensuring the safety and quality of water supplies by identifying microbial contaminants. The firm’s advanced diagnostic technologies significantly impact the animal health sector by delivering efficient, reliable diagnostics that enable proactive animal care. Idexx stands out as a key player in enhancing laboratory efficiency through its cloud-based practice management software, improving day-to-day operations for veterinary practices worldwide. Headquartered in Westbrook, Maine, Idexx Laboratories' mission and products underscore its vital role in advancing global animal health and environmental testing solutions, making it a significant entity in the health technology market.
Official SEC Documents
Advertisement